[go: up one dir, main page]

CL2004000566A1 - Sistema de liberacion controlada que contiene un componente farmaceuticamente activo, acetato de isobutirato de sacarosa (saib), y como disolvente glicerolformal o isopropilidenglicerol o una mezcla de los mismos. - Google Patents

Sistema de liberacion controlada que contiene un componente farmaceuticamente activo, acetato de isobutirato de sacarosa (saib), y como disolvente glicerolformal o isopropilidenglicerol o una mezcla de los mismos.

Info

Publication number
CL2004000566A1
CL2004000566A1 CL200400566A CL2004000566A CL2004000566A1 CL 2004000566 A1 CL2004000566 A1 CL 2004000566A1 CL 200400566 A CL200400566 A CL 200400566A CL 2004000566 A CL2004000566 A CL 2004000566A CL 2004000566 A1 CL2004000566 A1 CL 2004000566A1
Authority
CL
Chile
Prior art keywords
saib
controlled release
solvent
isopropilidenglicerol
isobutirate
Prior art date
Application number
CL200400566A
Other languages
English (en)
Inventor
Fraatz Dirk Mertin Ir Kristine
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of CL2004000566A1 publication Critical patent/CL2004000566A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SISTEMA DE LIBERACION CONTROLADA DE SUSTANCIAS MEDICINALMENTE ACTIVAS QUE CONTIENEN ACETATO ISOBUTIRATO DE SACAROSA (SAIB) ASI COMO UN DISOLVENTE ADICIONAL.
CL200400566A 2003-03-20 2004-03-18 Sistema de liberacion controlada que contiene un componente farmaceuticamente activo, acetato de isobutirato de sacarosa (saib), y como disolvente glicerolformal o isopropilidenglicerol o una mezcla de los mismos. CL2004000566A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10312346A DE10312346A1 (de) 2003-03-20 2003-03-20 Kontrolliertes Freisetzungssystem

Publications (1)

Publication Number Publication Date
CL2004000566A1 true CL2004000566A1 (es) 2005-02-04

Family

ID=32920993

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200400566A CL2004000566A1 (es) 2003-03-20 2004-03-18 Sistema de liberacion controlada que contiene un componente farmaceuticamente activo, acetato de isobutirato de sacarosa (saib), y como disolvente glicerolformal o isopropilidenglicerol o una mezcla de los mismos.

Country Status (18)

Country Link
US (1) US8231903B2 (es)
EP (1) EP1608335B1 (es)
JP (1) JP4863867B2 (es)
AR (1) AR043423A1 (es)
AT (1) ATE380017T1 (es)
AU (1) AU2004222646B2 (es)
BR (1) BRPI0408555A (es)
CA (1) CA2519351C (es)
CL (1) CL2004000566A1 (es)
DE (2) DE10312346A1 (es)
ES (1) ES2297396T3 (es)
GT (1) GT200400045A (es)
MX (1) MXPA05009910A (es)
NO (1) NO20054776L (es)
NZ (1) NZ542477A (es)
PE (1) PE20041024A1 (es)
TW (1) TW200505488A (es)
WO (1) WO2004082658A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
EP2959893A1 (en) 2002-12-13 2015-12-30 DURECT Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
GEP20094831B (en) * 2004-09-17 2009-11-25 Durect Corp Control release system
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
DE102006010643A1 (de) * 2006-03-08 2007-09-13 Bayer Healthcare Aktiengesellschaft Arzneimittel enthaltend Fluorchinolone
DE102006049520A1 (de) 2006-10-20 2008-04-24 Bayer Healthcare Ag Verfahren zur Herstellung von Pradofloxacin
EP2484347A1 (en) 2006-11-03 2012-08-08 Durect Corporation Transdermal delivery systems comprising bupivacaine
AU2008254538B2 (en) * 2007-05-18 2013-11-07 Durect Corporation Improved depot formulations
EP2219622A1 (en) 2007-12-06 2010-08-25 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
US8586103B2 (en) * 2008-02-08 2013-11-19 Foresee Pharmaceuticals, Llc Non-polymeric compositions for controlled drug delivery
US7923447B2 (en) * 2008-03-17 2011-04-12 Academic Pharmaceuticals Incorporated Parenteral solutions containing metolazone
US20110154725A1 (en) * 2008-03-28 2011-06-30 Sergey Dmitrievich Varfolomeev Agent for increasing the octane number of a gasoline automobile fuel
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
CN102764257B (zh) * 2011-10-21 2013-09-25 四川百利药业有限责任公司 一种马来酸氟吡汀缓释片剂
CN105120659A (zh) 2013-03-15 2015-12-02 度瑞公司 用于降低溶解可变性的具有流变改性剂的组合物
CN103520167A (zh) * 2013-10-30 2014-01-22 游锡火 含硫酸头孢喹诺和甲磺酸达氟沙星的长效注射剂
CN103520099A (zh) * 2013-10-30 2014-01-22 王玉万 含有效成份为沃尼妙林的长效注射剂
CN103520098A (zh) * 2013-10-30 2014-01-22 王玉万 恩诺沙星兽用长效注射剂的制备方法
CN103550149A (zh) * 2013-10-30 2014-02-05 游锡火 含抗寄生虫药物长效注射剂的制备技术
CN103550150B (zh) * 2013-10-30 2016-06-08 北京中农华威制药有限公司 改进的含二甲基硅油的注射剂
CN103536531A (zh) * 2013-10-30 2014-01-29 王玉万 甲磺酸达氟沙星长效注射剂制备方法
CN103520168A (zh) * 2013-10-30 2014-01-22 游锡火 含延胡索酸泰妙菌素的复方注射剂
CN103550148A (zh) * 2013-10-30 2014-02-05 游锡火 延胡索酸泰妙菌素长效注射剂制备方法
EP3481381B1 (en) 2016-07-06 2025-01-08 Orient Pharma Co., Ltd. Oral dosage form with drug composition, barrier layer and drug layer
MY204213A (en) 2018-04-25 2024-08-16 Bayer Animal Health Gmbh Process for the hydrolysis of quinolone carboxylic esters
KR20220054319A (ko) 2019-08-14 2022-05-02 비토퀴놀 에스에이 기생충 방제용 티골라너를 포함하는 조성물
KR20220140711A (ko) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법
CN116940358A (zh) 2021-01-12 2023-10-24 度勒科特公司 持续释放药物递送系统和有关的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5746986A (en) * 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
US4670444B1 (en) * 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
US4472405A (en) * 1982-11-12 1984-09-18 Riker Laboratories, Inc. Antimicrobial 6,7-dihydro-5,8-dimethyl-9 fluoro-1-oxo-1H, 5H-benzo (ij) quinolizine-2-carboxylic acid and derivatives
US4730000A (en) * 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
AT392789B (de) * 1985-01-23 1991-06-10 Toyama Chemical Co Ltd Verfahren zur herstellung von 1-substituierten aryl-1,4-dihydro-4-oxonaphthyridinderivaten
IN166416B (es) * 1985-09-18 1990-05-05 Pfizer
DE4319649A1 (de) * 1993-03-18 1994-09-22 Asta Medica Ag Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
CA2582666C (en) * 1994-04-08 2010-05-25 Qlt Usa, Inc. Controlled release implant
DE4416927C1 (de) * 1994-05-13 1995-08-31 Lohmann Therapie Syst Lts Vorrichtung zur Abgabe von Wirkstoffen aus Haftschmelzklebern, Verfahren zu ihrer Herstellung und ihre Verwendung
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5968542A (en) * 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
US6413536B1 (en) * 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
CA2247020C (en) * 1996-02-23 2005-11-08 Bayer Aktiengesellschaft Possibly substituted 8-cyano-1-cyclopropyl-7-(2,8-diazabicyclo-[4.3.0]-nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolin carboxylic acids and their derivatives
US6391336B1 (en) * 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US7128927B1 (en) * 1998-04-14 2006-10-31 Qlt Usa, Inc. Emulsions for in-situ delivery systems
NZ530701A (en) * 1999-06-04 2005-09-30 Alza Corp Implantable gel compositions comprising compressed particles including the active agent in a bioerodible gel
JP2003530308A (ja) 1999-08-03 2003-10-14 アーヴェーデー．ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト 犬および猫の退行性関節疾患に起因する痛みを軽減するためのフルピルチンの使用
WO2001078683A2 (en) * 2000-04-19 2001-10-25 Genentech, Inc. Sustained release formulations comprising growth hormone
IL159048A0 (en) * 2001-06-21 2004-05-12 Genentech Inc Sustained release formulation
US20050031650A1 (en) * 2002-08-26 2005-02-10 Ethypharm Composition with gelling properties for the sustained delivery of bioactive substances
DE10242088A1 (de) * 2002-09-11 2004-03-25 Bayer Ag Kontrolliertes Freisetzungssystem, welches Saccharoseacetatisobutyrat enthält

Also Published As

Publication number Publication date
CA2519351C (en) 2012-02-07
AU2004222646B2 (en) 2010-04-29
EP1608335A1 (de) 2005-12-28
PE20041024A1 (es) 2005-01-27
US20090246277A9 (en) 2009-10-01
JP2006520346A (ja) 2006-09-07
WO2004082658A1 (de) 2004-09-30
DE10312346A1 (de) 2004-09-30
AR043423A1 (es) 2005-07-27
GT200400045A (es) 2004-10-21
US20060034926A1 (en) 2006-02-16
ATE380017T1 (de) 2007-12-15
EP1608335B1 (de) 2007-12-05
DE502004005652D1 (de) 2008-01-17
US8231903B2 (en) 2012-07-31
BRPI0408555A (pt) 2006-03-21
ES2297396T3 (es) 2008-05-01
CA2519351A1 (en) 2004-09-30
NZ542477A (en) 2009-02-28
AU2004222646A1 (en) 2004-09-30
MXPA05009910A (es) 2005-11-04
JP4863867B2 (ja) 2012-01-25
NO20054776L (no) 2005-10-17
TW200505488A (en) 2005-02-16

Similar Documents

Publication Publication Date Title
CL2004000566A1 (es) Sistema de liberacion controlada que contiene un componente farmaceuticamente activo, acetato de isobutirato de sacarosa (saib), y como disolvente glicerolformal o isopropilidenglicerol o una mezcla de los mismos.
TR200100366T2 (tr) Aktif madde dağıtmaya mahsus bileşikler ve bileşimler.
WO2008008364A3 (en) Enhanced stability phenylephrine liquid compositions
AR047928A1 (es) Derivados de tetrahidropiridoindol
IL245365A0 (en) ATP-linked cassette transport modulators, pharmaceutical preparations containing them and their uses
DE602004027936D1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
WO2004066912A3 (en) Anti-inflammatory compositions and uses thereof
CL2003002770A1 (es) Compuestos derivados de pirrol e imiddazol; composiciones farmaceuticas que los contienen; procedimiento de preparacion; y su uso en el tratamiento y/o prevencion de enfermedades que estan asociadas con la modulacion de los receptores a canabinoides
DE602004017490D1 (de) Medizinische vorrichtungen
EA200501702A1 (ru) Устойчивая к манипуляциям дозировочная форма для трансдермального введения
EA200602033A1 (ru) Пестицидные смеси
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
PA8575701A1 (es) Preparaciones acidas de insulina con estabilidad mejorada
DE60038183D1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
WO2004089239A3 (en) Topical anthelmintic veterinary formulations
ECSP088203A (es) Dispersiones amorfas sólidas
ES2662320T3 (es) Sistema de matriz autoadhesiva que comprende un copolímero de bloques de estireno
EA200900267A1 (ru) КОМПОЗИЦИЯ ДЛЯ АЭРОЗОЛЬНОЙ ИНГАЛЯЦИИ β-АГОНИСТОВ И СТЕРОИДОВ
CL2004001678A1 (es) Compuestos derivados de oxazolidinona; composicion farmaceutica; y uso de los compuestos como agentes bacterianos.
WO2005097064A3 (en) Taste-masked drugs in rupturing multiparticulates
UY29701A1 (es) Formulaciones líquidas para la administración controlada de derivados de bencisoxazol
WO2008128191A3 (en) Oral cephalotaxine dosage forms
PA8577701A1 (es) Polipeptido t20 pegilado
EP1584335A3 (en) Active substance combination comprising a carbinol composition and an opioid
WO2005097087A3 (en) Merged ion channel modulating compounds and uses thereof